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Analysis of NOTCH1 mutations in monoclonal B cell lymphocytosis
Monoclonal B-cell lymphocytosis (MBL) represents asymptomatic monoclonal B-cell expansions characterized by a chronic lymphocytic leukemia (CLL)-phenotype, but with less than 5.0 x 10 9 /L circulating cells. [1] [2] [3] Clinical MBL (cMBL) are recognized during the diagnostic workup of an asymptomatic lymphocytosis. [4] [5] [6] Although the molecular pathogenesis of MBL is scarcely known, the biological indolence of this condition is documented by the rare occurrence of genetic lesions predicting poor prognosis in CLL, such as TP53 and ATM disruption. [4] [5] [6] Recently, two independent investigations of the CLL coding genome have revealed that activating mutations of the NOTCH1 proto-oncogene occur in ~10% CLL at diagnosis and their frequency increases in advanced disease phases, exemplified by the case of Richter syndrome. 7, 8 Initial evidence suggests that NOTCH1 alterations might predict an unfavorable clinical outcome in CLL. The prevalence of NOTCH1 mutations in MBL is currently unknown.
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Here we investigated the occurrence of NOTCH1 mutations in 63 consecutive cMBL presenting at our clinic for the initial evaluation of an asymptomatic lymphocytosis. The cMBL cohort was provided with prospectively collected peripheral blood mononuclear cell samples drawn at presentation, and with a prospectively maintained clinical database. All cMBL were analyzed for NOTCH1, TP53 and IGHV mutations by DNA Sanger sequencing, and for FISH karyotype using the LSI13 and LSID13S319, CEP12, LSIp53 and LSIATM probes (Abbott, Rome, Italy). 5,7 A NOTCH1 mutation (c.7544_7545delCT) that is known to be highly recurrent in CLL was also independently investigated by amplification refractory mutation system (ARMS) PCR. Patients provided informed consent in accordance with local IRB requirements and Declaration of Helsinki. To assess the prevalence of NOTCH1 mutations in cMBL, the NOTCH1 mutational hotspots identified in CLL (exons 26, 27 and 34; RefSeq NM_017617.2) were initially analyzed by Sanger sequencing of tumor DNA obtained at cMBL presentation. 7, 8 By this approach, NOTCH1 mutations occurred in only 2/63 (3.2%) cMBL, with a prevalence that was significantly lower than that observed in a large CLL dataset (70/603, 11.6%) (p=.050). In both cases, mutations were represented by a two bp frameshift deletion (c.7544_7545delCT) that represents the most recurrent (~80%) type of NOTCH1 mutation detectable in CLL (Figure 1 ). The sensitivity of DNA Sanger sequencing does not allow the identification of a mutation whose allelic representation is <10%. Because NOTCH1 mutations in CLL may be subclonal in a fraction of cases, and considering that the representation of peripheral blood monoclonal B cells in MBL is lower than in CLL, we reasoned that a mutation detection assay with a sensitivity higher than Sanger sequencing might be useful to define the true occurrence of NOTCH1 mutations in MBL. To this purpose, we specifically designed a high sensitivity ARMS PCR assay 12 
